ArticleThe Journal of veterinary medical science2026
Buddleja officinalis as a natural xanthine oxidase inhibitor in a murine hyperuricemia model.
Article in The Journal of veterinary medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buddleja officinalis Maxim. is rich in flavonoids and polyphenols, which exhibits pronounced antioxidant activity. Given that B. asiatica, a related species, has been noted to inhibit xanthine oxidase (XO) in vitro, the urate-lowering effects of B. officinalis have not been confirmed. Thus, this study aimed to screen the XO inhibition of extracts in vitro and to confirm the most active urate-lowering fraction of B. officinalis in vivo. Ethanol extracts were partitioned into n-hexane (HEX), ethyl acetate (EA), n-butanol (BuOH), and aqueous fractions. The EA fraction of B. officinalis extracts exhibited the highest XO inhibitory activity, with it significantly surpassing that of the other fractions (P<0.05). Consequently, the EA fraction was selected for further in vivo evaluation in a mouse model of hyperuricemia, which was induced through intraperitoneal injection of potassium oxonate (PO, 250 mg/kg/day for 7 days). Mice were divided into six groups, including not treated, PO, PO + allopurinol, and low (PO + EA-L), medium (PO + EA-M), and high (PO + EA-H) EA dose groups. EA fractions of B. officinalis extracts were orally administered 1 hr after PO injection. Compared with in the PO group, the serum uric acid levels were significantly reduced in the PO + EA-M, PO + EA-H, and PO + allopurinol groups (P<0.05). These findings support the potential of B. officinalis as a natural XO inhibitor and an adjunctive supplement for hyperuricemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.